[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335816-105":59,"doc-detail-335816-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pulmonary-adenocarcinoma-of-low-malignant-potential-defines-indolent-nsclc-associated-with-overdiagnosis-in-the-national-lung-screening-trial","Pulmonary adenocarcinoma of low malignant potential defines indolent NSCLC associated with overdiagnosis in the national lung screening trial","","Background: The national lung screening trial (NLST) showed reduced lung cancer mortality with low-dose CT (LDCT) versus chest X-ray (CXR), with high overdiagnosis among bronchoalveolar carcinoma (BAC) reclassified to adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), and adenocarcinoma of low malignant potential (LMP), each demonstrating 100% disease-specific survival (DSS). Objective: Compare BAC, AIS, MIA, and LMP proportions among NLST stage IA NSCLC with overall overdiagnosis rates. Methods: Whole-slide review of NLST-detected cases and overdiagnosis calculations from follow-up incidence.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pulmonary-adenocarcinoma-of-low-malignant-potential-defines-indolent-nsclc-associated-with-overdiagnosis-in-the-national-lung-screening-trial/335816/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pulmonary-adenocarcinoma-of-low-malignant-potential-defines-indolent-nsclc-associated-with-overdiagnosis-in-the-national-lung-screening-trial/335816.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study objective in relation to NLST overdiagnosis?","Question",{"text":112,"@type":113},"To compare the outcomes and proportions of BAC, AIS, MIA, and LMP among NLST screen-detected stage I A NSCLC and relate these proportions to the overdiagnosis rate.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were cases reviewed in the study methods?",{"text":117,"@type":113},"Whole slide images were reviewed by a thoracic pathologist from a digitized subset of 174 of 409 NLST screen-detected stage IA LUAD cases.",{"name":119,"@type":110,"acceptedAnswer":120},"What key result linked LMP/AIS/MIA to overdiagnosis and survival?",{"text":121,"@type":113},"The AIS/MIA/LMP proportion matched the overdiagnosis rate for stage IA NSCLC, and AIS/MIA/LMP showed 100% 7-year DSS, supporting the value of preoperative biomarkers to prevent overtreatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335816,1790372574,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Pulmonary adenocarcinoma of low malignant potential deﬁnes indolent NSCLC associated with overdiagnosis in the national lung screening trial  \nEric J. Burks 1,2, Travis B. Sullivan2 and Kimberly M. Rieger-Christ2  \nCancer Biomarkers Vol. 42(1): 1–10  \n© 2025 – The authors. Published by IOS Press.  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)DOI: 10.3233/CBM-230452 [journals.sagepub.com/home/cbm](journals.sagepub.com/home/cbm)  \nAbstract  \nBackground: The national lung screening trial (NLST) demonstrated a reduction in lung cancer mortality with lowdose CT (LDCT) compared to chest x-ray (CXR) screening. Overdiagnosis was high (79%) among bronchoalveolar carcinoma (BAC) currently replaced by adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) and adenocarcinoma of low malignant potential (LMP) exhibiting 100% disease speciﬁc survival (DSS).  \nObjective: Compare the outcomes and proportions of BAC, AIS, MIA, and LMP among NLST screendetected stage IANSCLC with overdiagnosis rate.  \nMethods: Whole slide images were reviewed by a thoracic pathologist from 174 of 409 NLST screen-detected stage IA LUAD. Overdiagnosis rates were calculated from follow-up cancer incidence rates.  \nResults: Most BAC were reclassiﬁed as AIS/MIA/LMP (20/35 = 57%). The 7-year DSS was 100% for AIS/MIA/LMP and 94% for BAC. Excluding AIS/MIA/LMP, BAC behaved similarly to NSCLC (7-year DSS: 86% vs. 83%, P = 0.85) The overdiagnosis rate of LDCT stage IA NSCLC was 16.6% at 11.3-years, matching the proportion of AIS/MIA/LMP (16.2%) but not AIS/MIA (3.5%) or BAC (22.8%).  \nConclusions: AIS/MIA/LMP proportionally matches the overdiagnosis rate among stage IA NSCLC in the NLST, exhibiting 100% 7-year DSS. Biomarkers designed to recognize AIS/MIA/LMP preoperatively, would be useful to prevent overtreatment of indolent screen-detected cancers.  \nKeywords  \nNLST, overdiagnosis, LMP, AIS, MIA  \nReceived: 11 October 2023; accepted: 26 April 2024  \n1. Introduction  \nThe national lung screening trial (NLST) demonstrated an overall mortality reduction of 20% at a median of 6.5-years after three annual lowdose CT-screenings (LDCT) compared to the control arm screened by chest X-ray (CXR) among high-risk smokers [1] . Mortality reduction was associated with a stage shift towards the detection of early-stage disease whereby the majority of NSCLC are curable by surgery alone. Two follow-up studies have reported the frequency of overdiagnosis, deﬁned as the excess cancers in the CXR-arm presenting clinically after screening cessation compared to the LDCT-arm at median time points of 6.4-years and 11.3-years [2,3] . The overdiagnosis rate for all cancers was reported as 18.5% at 6.4-years and 3.1% at 11.3-years; NSCLC as 22.5% at 6.4-years (not speciﬁcally  \nreported at 11.3-years); and BAC as 78.9% at both the 6.4-year and 11.3-year time period.  \nSince the study period of the NLST, BAC was abandoned as a pathologic entity and replaced by the more  \n1 Department of Pathology and Laboratory Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston Medical Center, Boston, MA, USA  \n2Department of Translational Research, Ian C. Summerhayes Cell and Molecular Biology Laboratory, Lahey Hospital and Medical Center, Burlington, MA, USA  \nCorresponding author:  \nEric J. Burks, Boston University Mallory Pathology Associates, 670 Albany Street, Suite 304, Boston, MA 02118, USA. Tel.: +1 617 414 4283;  \nFax: +1 617 414 5315.  \nEmail: [ejburks@bu.edu](ejburks@bu.edu)  \nCreative Commons Non Commercial CC BY-NC: This is an open access article distributed under the terms of the Creative Commons  \nAttribution Non-Commercial (CC BY-NC 4.0) License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nspeciﬁcally deﬁned entities of adenocarcinoma in situ (AIS), minimally invasive adeno","cbCaicBUCFoystg3","https://ap.wps.com/l/cbCaicBUCFoystg3","pdf",644498,"English","# Introduction\n## Background and definitions\n# Methods\n## Patients and samples\n# Results\n## Reclassification, DSS, and overdiagnosis rate matching\n# Conclusions","[{\"question\":\"What was the study objective in relation to NLST overdiagnosis?\",\"answer\":\"To compare the outcomes and proportions of BAC, AIS, MIA, and LMP among NLST screen-detected stage I A NSCLC and relate these proportions to the overdiagnosis rate.\"},{\"question\":\"How were cases reviewed in the study methods?\",\"answer\":\"Whole slide images were reviewed by a thoracic pathologist from a digitized subset of 174 of 409 NLST screen-detected stage IA LUAD cases.\"},{\"question\":\"What key result linked LMP/AIS/MIA to overdiagnosis and survival?\",\"answer\":\"The AIS/MIA/LMP proportion matched the overdiagnosis rate for stage IA NSCLC, and AIS/MIA/LMP showed 100% 7-year DSS, supporting the value of preoperative biomarkers to prevent overtreatment.\"}]","Pulmonary adenocarcinoma of low malignant potential defines indolent NSCLC associated with overdiagnosis in the national lung screening trial | PDF",1790012411,25]